Results 101 to 110 of about 18,950,887 (401)

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Roadmap to 2030 for Drug Evaluation in Older Adults

Clinical pharmacology and therapy, 2021
Qi Liu, J. Schwartz, P. Slattum, S. Lau, Daphne Guinn, R. Madabushi, G. Burckart, R. Califf, F. Cerreta, Carolyn R Cho, J. Cook, J. Gamerman, P. Goldsmith, P. Graaf, J. Gurwitz, S. Haertter, S. Hilmer, Shiew-Mei Huang, S. Inouye, B. Kanapuru, M. Pirmohamed, Phil Posner, B. Radziszewska, H. Keipp Talbot, R. Temple   +24 more
semanticscholar   +1 more source

New South Wales drug court evaluation: Cost-effectiveness, CHERE Project Report 17a [PDF]

In this report we examine an issue central to the creation of the NSW Drug Court: namely its cost-effectiveness, compared with conventional sanctions, in reducing drug-related crime.
Bronwyn Lind, Don Weatherburn, Emily Lancsar, Marian Shanahan, Marion Haas, Shuling Chen   +5 more
core  

Cost-effectiveness of Methadone Maintenance Treatment in prevention of HIV among drug users in Shiraz, south of Iran [PDF]

, 2014
Background: The increase in high-risk injections and unsafe sexual behaviors has led to increased HIV infection prevalence among Intravenous Drug Users (IDUs). The high costs of HIV/AIDS care and low financial resources necessitate an economic evaluation
Heidari, A., Javanbakht, M., Keshtkaran, A., Mirahmadizadeh, A.   +3 more
core   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Performance of a Brief Assessment Tool for Identifying Substance Use Disorders [PDF]

, 2003
Objective: Evaluation of the performance of a brief assessment tool for identifying substance use disorders. The Triage Assessment for Addictive Disorders (TAAD) is a triage instrument that provides professionals with a tool to evaluate indications of ...
Campbell, Todd, Hoffman, Norman G, Madson, Michael B, Melchert, Timothy   +3 more
core   +1 more source

A programme for risk assessment and minimisation of progressive multifocal leukoencephalopathy developed for vedolizumab clinical trials [PDF]

, 2018
Introduction Over the past decade, the potential for drug-associated progressive multifocal leukoencephalopathy (PML) has become an increasingly important consideration in certain drug development programmes, particularly those of immunomodulatory ...
Berger, Joseph R, Clifford, David B, Fox, Irving, Lev, Michael H, Major, Eugene, McAuliffe, Megan, Milch, Catherine, Parikh, Asit, Patti, Mark, Provenzale, James M, Sankoh, Serap, Shick, Jesse, Stephens, Kristin   +12 more
core   +3 more sources

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Clinical pharmacology and therapy, 2018
Drug transporters can govern the absorption, distribution, metabolism, and excretion of substrate drugs and endogenous substances. Investigations to examine their potential impact to pharmacokinetic (PK) drug‐drug interactions (DDIs) are an integral part
X. Chu, M. Liao, Hong Shen, Kenta Yoshida, A. Zur, V. Arya, A. Galetin, K. Giacomini, Imad Hanna, H. Kusuhara, Yurong Lai, D. Rodrigues, Y. Sugiyama, M. Zamek-Gliszczynski, Lei Zhang   +14 more
semanticscholar   +1 more source

A review of the evidence for the effectiveness of primary prevention interventions for Hepatitis C among injecting drug users [PDF]

, 2006
BACKGROUND Hepatitis C (HCV) prevalence is most common amongst injecting drug users where up to 98% of the population can be infected despite a low prevalence of HIV.
Tompkins, C.N.E., Wright, N.M.J.
core   +3 more sources